** Brokerage H.C. Wainwright starts coverage on gene editing firm Intellia Therapeutics NTLA.O with "buy" rating, sets PT at $30
** Brokerage sees significant upside to NTLA's lead therapy candidate, NTLA-2002, for a type of heart disease known as hereditary angioedema
** The CRISPR-based therapy offers a one-time treatment for the condition with comparable efficacy to preventive treatments — brokerage
** NTLA is also developing a gene therapy, nexiguran ziclumeran (Nex-Z), to treat transthyretin amyloidosis, a condition that causes protein buildup in the heart
** "We believe the dramatic 2024 stock pullback, taking the market cap from ~$2.7B to ~$1.0B today, presents a compelling opportunity to own NTLA ahead of 2025 catalysts" — H.C. Wainwright
** NTLA has fallen ~72% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.